Arbutus Biopharma Corp (ABUS)
3.635
-0.10
(-2.68%)
USD |
NASDAQ |
Nov 12, 15:16
Arbutus Biopharma Revenue (TTM): 6.742M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 6.742M |
| June 30, 2024 | 10.06M |
| March 31, 2024 | 12.99M |
| December 31, 2023 | 18.14M |
| September 30, 2023 | 22.24M |
| June 30, 2023 | 23.54M |
| March 31, 2023 | 33.12M |
| December 31, 2022 | 39.02M |
| September 30, 2022 | 35.98M |
| June 30, 2022 | 33.37M |
| March 31, 2022 | 21.46M |
| December 31, 2021 | 10.99M |
| September 30, 2021 | 10.17M |
| June 30, 2021 | 8.351M |
| March 31, 2021 | 7.536M |
| December 31, 2020 | 6.914M |
| September 30, 2020 | 6.146M |
| June 30, 2020 | 7.684M |
| March 31, 2020 | 6.823M |
| December 31, 2019 | 6.011M |
| September 30, 2019 | 6.071M |
| June 30, 2019 | 4.597M |
| March 31, 2019 | 5.188M |
| December 31, 2018 | 5.945M |
| September 30, 2018 | 6.801M |
| Date | Value |
|---|---|
| June 30, 2018 | 12.11M |
| March 31, 2018 | 11.90M |
| December 31, 2017 | 10.70M |
| September 30, 2017 | 7.971M |
| June 30, 2017 | 1.853M |
| March 31, 2017 | 1.123M |
| December 31, 2016 | 1.491M |
| September 30, 2016 | 12.78M |
| June 30, 2016 | 16.07M |
| March 31, 2016 | 19.20M |
| December 31, 2015 | 23.28M |
| September 30, 2015 | 16.54M |
| June 30, 2015 | 16.83M |
| March 31, 2015 | 15.20M |
| December 31, 2014 | 14.95M |
| September 30, 2014 | 18.13M |
| June 30, 2014 | 16.73M |
| March 31, 2014 | 17.76M |
| December 31, 2013 | 15.47M |
| September 30, 2013 | 11.65M |
| June 30, 2013 | 11.78M |
| March 31, 2013 | 12.50M |
| December 31, 2012 | 13.94M |
| September 30, 2012 | 14.60M |
| June 30, 2012 | 15.51M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
6.011M
Minimum
Dec 2019
39.02M
Maximum
Dec 2022
16.36M
Average
10.58M
Median
Revenue (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 2.753B |
| Amicus Therapeutics Inc | 493.67M |
| Ionis Pharmaceuticals Inc | 803.07M |
| GlycoMimetics Inc | -- |
| FibroGen Inc | 173.82M |